Following the AAD VMX meeting we caught up with Prof. Amy S. Paller (Northwestern University Feinberg School of Medicine, Chicago, IL, USA) to discuss some of the presentations and recent advances being made in the treatment of children with atopic dermatitis.
Disclosures: Prof. Amy Paller has acted as a consultant with honorarium for AbbVie, Abeona, Alcimed, Almirall, Amagma, Anaptysbio, Arena, Azitra, BiomX, Boehringer Ingelheim, Castle Biosciences, Catawba, Dermira, Eli Lilly, Exicure, Forte, Galderma, Kamari, Leo, Lifemax, NAOS, Novartis, Pfizer, Phoenix, Pierre Fabre, Sanofi/Genzyme, Seanergy, Trifecta and UCB; and an investigator (to institution) for AbbVie, Eli Lilly, Janssen, Regeneron, Incyte and UCB.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of the AAD VMX 2021.
Share this Video
Related Videos In Atopic Dermatitis
Andy Blauvelt, EADV 2021: Switching from Dupilumab to Upadacitinib in Atopic Dermatitis
It was a pleasure to speak with Dr Andy Blauvelt (Oregon Medical Research Center, Portland, OR, USA) about the results from the recent open-label study investigating the efficacy and safety of switching from dupilumab to upadacitinib in the treatment of atopic dermatitis. His presentation entitled ‘Efficacy and Safety of Switching from Dupilumab to Upadacitinib in […]
Kim Papp, AAD VMX 2021: Ruxolitinib Phase 3 Subgroup Analysis
It was a pleasure to speak with Dr Kim Papp (Probity Medical Research, Waterloo, ON, Canada) around the efficacy and tolerability of ruxolitinib cream in the treatment of atopic dermatitis (NCT03745638 & NCT03745651). The abstract ‘Efficacy of Ruxolitinib Cream for the Treatment of Atopic Dermatitis by Baseline Clinical Characteristics: Pooled Subgroup Analysis From Two Randomized […]
Amy S. Paller, AAD VMX: Dupilumab LIBERTY AD PEDS Trial
We were delighted to speak with Prof. Amy S. Paller (Northwestern University Feinberg School of Medicine, Chicago, IL, USA) about the results from the phase 3, LIBERTY AD PEDS trial (NCT03345914). This double-blind, 16-week study investigated duplimuab in children with atopic dermatitis. Her abstract entitled ‘Dupilumab Provides Clinically Meaningful Improvement in Atopic Dermatitis (AD) Signs, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!